Literature DB >> 25862987

Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease.

Ioannis E Koutroubakis1, Claudia Ramos-Rivers1, Miguel Regueiro1, Efstratios Koutroumpakis1, Benjamin Click1, Robert E Schoen1, Jana G Hashash1, Marc Schwartz1, Jason Swoger1, Leonard Baidoo1, Arthur Barrie1, Michael A Dunn1, David G Binion2.   

Abstract

BACKGROUND & AIMS: Anemia is a common manifestation of inflammatory bowel disease (IBD) that can greatly affect patients' quality of life. We performed a prospective study of a large cohort of patients with IBD to determine if patterns of anemia over time are associated with aggressive or disabling disease.
METHODS: We performed a longitudinal analysis of demographic, clinical, laboratory, and treatment data from a registry of patients with IBD at the University of Pittsburgh Medical Center from 2009 through 2013. Patients with a complete follow-up evaluation (at least 1 annual visit with laboratory results) were included. Anemia was defined by World Health Organization criteria. Disease activity scores (the Harvey-Bradshaw Index or the ulcerative colitis activity index) and quality-of-life scores (based on the short IBD questionnaire) were determined at each visit; laboratory data, including levels of C-reactive protein and erythrocyte sedimentation rates, as well as patterns of IBD-related health care use, were analyzed.
RESULTS: A total of 410 IBD patients (245 with Crohn's disease, 165 with ulcerative colitis; 50.5% female) were included. The prevalence of anemia in patients with IBD was 37.1% in 2009 and 33.2% in 2013. Patients with IBD and anemia required significantly more health care and had higher indices of disease activity, as well as a lower average quality of life, than patients without anemia (P < .0001). Anemia (persistent or recurrent) for 3 or more years was correlated independently with hospitalizations (P < .01), visits to gastroenterology clinics (P < .001), telephone calls (P < .004), surgeries for IBD (P = .01), higher levels of C-reactive protein (in patients with ulcerative colitis, P = .001), and a higher erythrocyte sedimentation rate (P < .0001). Anemia was correlated negatively with quality-of-life scores (P < .03).
CONCLUSIONS: Based on a longitudinal analysis of 410 patients, persistent or recurrent anemia correlates with more aggressive or disabling disease in patients with IBD.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-Reactive Protein; Crohn's Disease; Erythrocyte Sedimentation Rate; Quality of Life; Ulcerative Colitis

Mesh:

Substances:

Year:  2015        PMID: 25862987      PMCID: PMC4702483          DOI: 10.1016/j.cgh.2015.03.029

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  27 in total

Review 1.  Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease.

Authors:  Wojciech Blonski; Anna M Buchner; Gary R Lichtenstein
Journal:  Gastroenterol Clin North Am       Date:  2012-06       Impact factor: 3.806

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

3.  The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.

Authors:  Ioannis E Koutroubakis; Claudia Ramos-Rivers; Miguel Regueiro; Efstratios Koutroumpakis; Benjamin Click; Marc Schwartz; Jason Swoger; Leonard Baidoo; Jana G Hashash; Arthur Barrie; Michael A Dunn; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

4.  Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease.

Authors:  Pantelis Oustamanolakis; Ioannis E Koutroubakis; Ippokratis Messaritakis; Georgios Kefalogiannis; Maria Niniraki; Elias A Kouroumalis
Journal:  J Crohns Colitis       Date:  2011-04-03       Impact factor: 9.071

5.  Anaemia and iron deficiency in children with inflammatory bowel disease.

Authors:  Anthony E Wiskin; Ben J Fleming; Stephen A Wootton; R Mark Beattie
Journal:  J Crohns Colitis       Date:  2012-01-17       Impact factor: 9.071

6.  Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.

Authors:  Christoph Gasche; Arnold Berstad; Ragnar Befrits; Christoph Beglinger; Axel Dignass; Kari Erichsen; Fernando Gomollon; Henrik Hjortswang; Ioannis Koutroubakis; Stefanie Kulnigg; Bas Oldenburg; David Rampton; Oliver Schroeder; Jürgen Stein; Simon Travis; Gert Van Assche
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

Review 7.  Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature.

Authors:  Alisa Wilson; Eileen Reyes; Josh Ofman
Journal:  Am J Med       Date:  2004-04-05       Impact factor: 4.965

8.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

9.  Health-related quality of life in patients with inflammatory bowel disease: a single-center experience.

Authors:  Maria Kalafateli; Christos Triantos; Georgios Theocharis; Dimitra Giannakopoulou; Efstratios Koutroumpakis; Aristidis Chronis; Apostolos Sapountzis; Vasileios Margaritis; Konstantinos Thomopoulos; Vasiliki Nikolopoulou
Journal:  Ann Gastroenterol       Date:  2013

10.  Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study.

Authors:  Florian Rieder; Gisela Paul; Elisabeth Schnoy; Stephan Schleder; Alexandra Wolf; Florian Kamm; Andrea Dirmeier; Ulrike Strauch; Florian Obermeier; Rocio Lopez; Jean-Paul Achkar; Gerhard Rogler; Frank Klebl
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

View more
  22 in total

1.  Analysis of Hospital-Based Emergency Department Visits for Inflammatory Bowel Disease in the USA.

Authors:  Mahesh Gajendran; Chandraprakash Umapathy; Priyadarshini Loganathan; Jana G Hashash; Ioannis E Koutroubakis; David G Binion
Journal:  Dig Dis Sci       Date:  2015-09-30       Impact factor: 3.199

2.  Improving IBD Care: A Personalized Approach to Management.

Authors:  Stephen B Hanauer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

3.  Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.

Authors:  Efstratios Koutroumpakis; Claudia Ramos-Rivers; Miguel Regueiro; Jana G Hashash; Arthur Barrie; Jason Swoger; Leonard Baidoo; Marc Schwartz; Michael A Dunn; Ioannis E Koutroubakis; David G Binion
Journal:  Dig Dis Sci       Date:  2015-10-29       Impact factor: 3.199

4.  Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.

Authors:  Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-17       Impact factor: 11.382

5.  Risk factors of surgical site infections in patients with Crohn's disease complicated with gastrointestinal fistula.

Authors:  Kun Guo; Jianan Ren; Guanwei Li; Qiongyuan Hu; Xiuwen Wu; Zhiwei Wang; Gefei Wang; Guosheng Gu; Huajian Ren; Zhiwu Hong; Jieshou Li
Journal:  Int J Colorectal Dis       Date:  2017-01-16       Impact factor: 2.571

6.  Factors Associated with Short-Term Morbidity in Patients Undergoing Colon Resection for Crohn's Disease.

Authors:  H Hande Aydinli; Erman Aytac; Feza H Remzi; Mitchell Bernstein; Alexis L Grucela
Journal:  J Gastrointest Surg       Date:  2018-04-16       Impact factor: 3.452

7.  Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.

Authors:  Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

8.  Anemia Severity Associated with Increased Healthcare Utilization and Costs in Inflammatory Bowel Disease.

Authors:  Hanna Blaney; Peter Vu; Antony Mathew; Robin Snelling; Julie England; Camille Duong; Kendall Hammonds; Christopher Johnson
Journal:  Dig Dis Sci       Date:  2020-09-05       Impact factor: 3.199

9.  Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial.

Authors:  David S Rampton; James R Goodhand; Neerav M Joshi; Abu-Bakarr Karim; Yasmine Koodun; Farah M Barakat; Lucia Macken; Douglas G Ward; Tariq H Iqbal; Jenny Epstein; John M Fell; Ian R Sanderson
Journal:  J Crohns Colitis       Date:  2017-06-01       Impact factor: 9.071

10.  Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry.

Authors:  Alyce Anderson; Cynthia Cherfane; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Dmitriy Babichenko; Gong Tang; Michael Dunn; Arthur Barrie; Siobhan Proksell; Jeffrey Dueker; Elyse Johnston; Marc Schwartz; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2022-01-05       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.